Drug updated on 11/15/2023

Dosage FormInjection (subcutaneous; 0.4 mg, 0.56 mg, 1.2 mg)
Drug ClassC type natriuretic peptide analogs
Ongoing and Completed StudiesClinicalTrials.gov


  • Indicated to increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses.

Product Monograph / Prescribing Information

Document TitleYearSource
Voxzogo (vosoritide) Prescribing Information.2023BioMarin Pharmaceutical Inc., Novato, CA

Systematic Reviews / Meta-Analyses